Fundraising Fox

Grannus Therapeutics

Indianapolis, US · Founded 2020 · United States corporation · 2 known investors

Grannus Therapeutics develops Hsp90 inhibitors that selectively target the beta isoform of the Hsp90 protein for cancer treatment. Its lead candidate, GRE317, is designed for single-agent anti-tumor activity and combination with therapies such as PARP inhibitors and immunotherapies, with programs advancing toward IND-enabling milestones and clinical studies.

BiotechHealthtech

Founders & leadership

Grannus Therapeutics was founded in 2020 by Brian Blagg and Sanket Mishra.

BB
Brian BlaggCo-founder
SMSanket Mishra
Sanket MishrainCo-Founder and VP preclinical R&D
JFJohn Foglesong
John FoglesongNamed on SEC filing
JT
James ThompsonNamed on SEC filing

Investors · 2

1842Notre Dame
Elevate VenturesIndianapolis · $20K – $2M

Reported raises · per SEC filings

Form D private placements

$1.8M disclosed across 2 rounds · 2022–2023

▶$800KraisedJan 2024 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John FoglesongExecutive Officer, Director
  • Brian BlaggDirector
Offering amount
$800K
Amount sold
$800K
Minimum investment
$250K
First sale
Nov 2023
Incorporated
Corporation, United States, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$950KraisedJan 2022 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John FoglesongExecutive Officer, Director
  • James ThompsonDirector
  • Brian BlaggDirector
Offering amount
$1M
Amount sold
$950K
Minimum investment
$35K
First sale
Jan 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
Transcode Therapeutics8 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
Linnaeus Therapeutics5 shared keywordsClinical-stage biotech company developing small molecule agents modulating cellular differentiation for cancer and pigmentation disorders.
Marengo Therapeutics5 shared keywordsMarengo Therapeutics is a clinical-stage biotech company developing TCR-targeting antibodies that activate specific T cell subsets by targeting Variable β (Vβ) chain variants of the T cell receptor. Its approach aims to modulate the immune system to treat cancer and other diseases.
Northwest Biotherapeutics4 shared keywordsNorthwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines, marketed under the DCVax platform, that use activated dendritic cells to treat a range of solid tumor cancers. Its product lines include DCVax-L, DCVax-Direct, and DCVax-Prostate.

Companies competing with Grannus Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Grannus Therapeutics do?
Grannus Therapeutics develops Hsp90 inhibitors that selectively target the beta isoform of the Hsp90 protein for cancer treatment. Its lead candidate, GRE317, is designed for single-agent anti-tumor activity and combination with therapies such as PARP inhibitors and immunotherapies, with programs advancing toward IND-enabling milestones and clinical studies.
Who founded Grannus Therapeutics?
Grannus Therapeutics was founded by Brian Blagg, Sanket Mishra in 2020.
Who are Grannus Therapeutics's investors?
Grannus Therapeutics's investors include 1842, Elevate Ventures.
How much funding has Grannus Therapeutics raised?
Grannus Therapeutics has disclosed $1.8M raised across 2 rounds.
Where is Grannus Therapeutics headquartered?
Grannus Therapeutics is headquartered in Indianapolis, US.